Stocksigma LogoStocksigma Logo

Cohance Lifesciences Advances ADC Strategy with $18M Investment in NJ Bio and Aruka Bio

Cohance Lifesciences will invest $18M via internal accruals to strengthen its Antibody-Drug Conjugate (ADC) capabilities

Cohance Lifesciences Advances ADC Strategy with $18M Investment in NJ Bio and Aruka Bio

Cohance Lifesciences Ltd 路 Others (Uncategorized) 路 04 Sept 2026, 1:23 am

Cohance Lifesciences Advances ADC Strategy with $18M Investment in NJ Bio and Aruka Bio Cohance Lifesciences will invest $18M via internal accruals to strengthen its Antibody-Drug Conjugate (ADC) capabilities. Closing by Sep'26, the deal includes a $13M outlay for 244,587 additional shares of NJ Bio at $53/share, raising Cohance's stake from 56% to 67.3%. Concurrently, Cohance will invest $5M for a 65% controlling stake in Aruka Bio, a preclinical ADC platform. The reorganization integrates NJ Bio's CRDMO services with Cohance's manufacturing, while accelerating Aruka's proprietary pipeline. Dr. Naresh Jain will serve as CEO for both subsidiaries to drive commercial alignment.

Original exchange filing (PDF)

More announcements from Cohance Lifesciences Ltd

All Cohance Lifesciences Ltd announcements